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Estimating efficacy in trials with
selective crossover
Adam R. Brentnall,*† Peter Sasieni and Jack Cuzick
When one arm in a trial has a worse early endpoint such as recurrence, a data-monitoring committee might rec-
ommend that all participants are offered the apparently superior treatment. The resultant crossover makes it
difficult to measure differences between arms thereafter, including for longer-term endpoints such as mortality
and disease-specific mortality. In this paper, we consider estimators of the efficacy of treatment on those who
would not cross over if randomised to the apparently inferior arm. Binomial and proportional hazards maximum
likelihood estimators are developed. The binomial estimator is applied to analysis of a breast cancer treatment
trial and compared with intention-to-treat and inverse probability weighting estimators. Full and partial likeli-
hood proportional-hazard model estimators are assessed through computer simulations, where they had similar
bias and variance. The new efficacy estimators extend those for all-or-none compliance to this important problem.
© 2017 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.
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1. Introduction
Unplanned crossover occurs in randomised trials when participants decide to switch treatment arms. It
makes it more difficult to measure a difference between arms, especially when there is selective crossover
because those who switch have a different background risk than others. In this paper, we consider trials
with selective crossover in one arm arising due to results from early efficacy endpoints, such as when
initial results from a trial or other concurrent trials lead a data-monitoring committee to recommend that
all participants are offered the apparently superior treatment. This form of crossover is represented using
a lexis diagram in Figure 1. It occurred in the BIG-1 98 trial, where women were randomised to receive
5 years of either letrozole or tamoxifen to prevent breast cancer recurrence. Initial results [1] led the
organisers to inform women in the tamoxifen monotherapy arms of their treatment, in order to allow an
informed decision about future care; one quarter of those in the tamoxifen arm switched to letrozole [2].
The traditional inferential method for a trial with selective crossover is an intention-to-treat (ITT)
analysis. This maintains the randomised balance of all causal factors other than the treatment, but it is
likely to attenuate the estimated effect of treatment, because some participants in the control arm receive
the intervention. A per-protocol approach censors those who cross over in the analysis, but it is unreliable
when crossover is informative because bias may occur in either direction and inference is compromised
[3]. Instead of these, we focus in this article on the effect of treatment on those who would not cross over
when offered if randomised to control. Although this may also be biased for the effect of treatment on
everyone in the trial, it is still of interest to identify the effect of treatment on those who would receive
it for the duration, and these are the only individuals who provide information on treatment effects over
the complete follow-up period.
Efficacy is defined more formally using a model with two latent strata. The first latent stratum contains
insistors, who would cross over to treatment when offered if randomised to control; the second consists
of ‘ambivalents’, who would not cross over when offered if randomised to control. The strata are shown
Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse
square, London EC1M 6BQ, U.K.
*Correspondence to: Adam R. Brentnall, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary
University of London, Charterhouse square, London EC1M 6BQ, U.K.
†E-mail: a.brentnall@qmul.ac.uk
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited.
© 2017 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd Statist. Med. 2017
A. R. BRENTNALL, P. SASIENI AND J. CUZICK
Figure 1. A lexis diagram representing survival and crossover. Each diagonal line is a person followed until they
have the event and the line stops; censoring only occurs after 10-year calendar time for clarity. [Colour figure can
be viewed at wileyonlinelibrary.com]
Figure 2. Hypothetical example to show the assumed latent strata in both trial arms when the endpoint is disease-
free survival. Each solid box contains observable data; efficacy compares ambivalents in the line-dot boxes (— -
- -). [Colour figure can be viewed at wileyonlinelibrary.com]
using an example in Figure 2. No one in the treatment arm switches to control, so there are assumed to
be no individuals who defy randomisation by taking the opposite treatment, or who would always switch
from treatment to control. The latent strata are unobserved in both arms prior to crossover, and only
partially revealed in the control arm. Efficacy measures the average difference between the ambivalents
in the two treatment arms.
Figure 2 is a suitable schematic for analysis of disease-free survival such as in the BIG-1 98 trial, but
it does not adequately show subtle complications that arise for a mortality endpoint. Figure 3 illustrates
the flow of patients under the model in the control arm when death is also included. The additional issue
is that the underlying strata of participants in the control arm are not revealed after unblinding for those
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Figure 3. Hypothetical example to show assumed latent class structure in control when the endpoint is mortality.
still alive but whose disease progressed beforehand. If this information was ignored, then the insistors in
control with a recurrence before the offer to switch would be incorrectly identified as ambivalent.
We view the model as a plausible description of the trial population when there is a difference in
underlying risk after crossover between those who switch treatment and the entire treatment arm. Models
with similar latent strata have been applied to different problems [4], including when they are revealed
at baseline [5–7] and when they are revealed after baseline [8]. A consequence of the two-strata model
is that the proportion of insistors at risk is likely to be different at baseline from the time of potential
crossover.
The unobserved boxes in Figure 2 show why the estimation problem is difficult. The marginal effect
of treatment may be estimated before crossover by comparing the two arms without adjustment. After
crossover, insistors in control receive the treatment. If the ambivalents were observed in both arms after
the offer, then estimation of efficacy would be straightforward. The problem is that they are missing
data before crossover in control and all the time in treatment. The remainder of the article considers this
estimation problem.
2. Binomial model
A binary model may be applied to analysis of a trial when events are rare and little information is con-
tained in the follow-up or event time of patients. It also provides insight into assumptions and parameter
identifiability aspects.We next focus on themodel illustrated by Figure 2, but themethodsmay be adapted
to mortality endpoints such as in Figure 3 by ensuring that the latent strata are unknown throughout
follow-up for those with a recurrence before the opportunity to cross over.
2.1. Assumptions
The first assumption is as follows:
(A1) The potential time of crossover (time when the patient would cross over if an insistor and
randomised to control) is observable for all participants in both arms.
This holds for the type of crossover shown by Figure 1. Using A1, we may take two time
periods before and after the offer (potential crossover time) and parameterise the probability ptrk
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of an event in period t = 0, 1 (before, after the offer), treatment arm r = 0, 1 (control, treatment)
and latent insistor stratum k = 0, 1 (ambivalent, insistor) as follows. For ambivalents (k = 0) in
control (r = 0) and periods t = 0, 1
pt00 = 𝛼t,
where 0 ⩽ 𝛼t ⩽ 1 is an unknown probability of the event (if a constant rate 𝛼∗ ⩾ 0 is assumed
and the time at risk Tt is known, then 𝛼t = 1−exp(−𝛼∗Tt), so that 𝛼t in both periods only depends
on a single unknown parameter). Efficacy 𝛾t in period t = 0, 1 is defined as the ratio between the
treated and untreated ambivalents
𝛾t = pt10∕pt00.
Insistors in the treatment arm are taken to differ from the ambivalents in period t = 0, 1 through
𝜔t = pt11∕pt10.
We also assume the following:
(A2) The treatment effect prior to the offer is the same for the ambivalents and insistors, so that
p011∕p001 = 𝛾0, or equivalently
p001∕p000 = 𝜔0.
A pragmatic reason for taking assumption A2 is that it ensures that the conditional treat-
ment effect among ambivalents before the offer matches the marginal effect (seen hereafter in
Equation (2)), which would be the primarymeasure for an ITT analysis of a trial without selective
crossover.
After the offer to switch, we allow a different treatment effect for the insistors in control
through
p101 = 𝛼1𝜔1𝛾∗1 ,
where 𝛾∗1 need not equal 𝛾1. For example, a treatment crossover effect may exist, such as resulting
from receiving a drug in control then the different drug from the treatment arm (which would
not have been the case at baseline for those randomised to treatment). Alternatively, this might
represent a difference in the treatment effect for insistors and ambivalents, and so testing whether
𝛾∗1 = 𝛾1 is a way to partially verify A2, albeit after the offer. We require two further assumptions:
(A3) The probability 𝜋 of being in strata k = 1 (insistor) at baseline is the same in both arms because
of randomisation.
(A4) Censoring is independent of strata k = 0, 1.
A4 may be partly verified by using data in the control arm after the offer to switch and inspecting
censoring in the other observed groups prior to and after the offer. Equivalent versions of A3 and A4 have
been used by all-or-none compliance estimators [7].
2.2. Identifiability
Six observable statistics depend on the model parameters. These are the total number of events in arm
r = 0, 1 in the first period y0r, the number of insistors n101 (or ambivalents n100) in control after the offer,
the number of events in the second period in control ambivalents y100 and insistors y101, and the number
of events in the treatment arm in the second period y11. The number censored d0r in the first period in
each arm r is an ancillary statistic, and binomial distributions are conditional upon the number ntr in each
arm r at risk at the start of each period t. The expected values of the observable statistics relate to the
model as follows. Before the offer, the expected proportion of events in control is
E(Y00)∕n00 = 𝜋𝛼0𝜔0 + (1 − 𝜋)𝛼0, (1)
and in the treatment arm it is
E(Y01)∕n01 = 𝛾0E(Y00)∕n00. (2)
At the offer to cross over, we observe the number of insistors still at risk in control n101, where
E(N101) = 𝜋n00 − E(Y00)
{
𝜋𝜔0
(1 − 𝜋) + 𝜋𝜔0
}
− d00𝜋, (3)
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which subtracts the expected number of events and censored (assumption A4) in insistors from the
expected number enrolled in control at baseline. The term compounded by E(Y00) is the probability that
the events are insistors. In the treatment arm, the number of insistors at risk at the offerN111 is unobserved,
but the expected value has the same form as Equation (3) with r = 1 in the subscripts rather than r = 0.
Thus, in the first period, there are three equations but four unknowns (𝜋, 𝛼0, 𝜔0, 𝛾0). The only parameter
that is uniquely identifiable without further constraints is the treatment effect 𝛾0, replacing expectations
by observed values in Equation (2). After the offer to switch the expected proportion of events in three
observed groups (cf. Figure 2) is
E(Y100)∕n100 = 𝛼1 (4)
E(Y101)∕n101 = 𝛾∗1𝛼1𝜔1 (5)
E(Y11)∕n11 = 𝛾1{𝜋11𝛼1𝜔1 + (1 − 𝜋11)𝛼1}, (6)
where 𝜋11 is the probability that individuals at risk in the treatment arm after the offer are insistors.
These equations help to assess identifiability of the model. Replacing the expectation with the observed
value in Equation (4) provides an estimate of 𝛼1. There is one degree of freedom for ?̂?0 and ?̂? (𝜋 may be
expressed as a polynomial function of 𝜔0 via Equation (3) and ?̂?11 = Ê(N111)∕n11). It might be important
to allow for different rates in both periods, so that 𝛼0 and 𝛼1 cannot be tied together through an constant-
rate assumption. For example, risk of death increases with age. After incorporating (𝛼0, 𝛼1, 𝜔0, 𝛾0), we
have three unknowns (𝜔1, 𝛾1, 𝛾∗1 ) and two degrees of freedom. However, this is not very restrictive because
our a priori assumption is that 𝛾0 = 𝛾1 = 𝛾∗1 , partly because we are interested in an overall measure of
treatment efficacy over the entire period of follow-up, and 𝜔0 = 𝜔1 is also our primary model. The ability
to check these assumptions contrasts favourably with an ITT analysis, where it would be very difficult to
check whether the treatment effect is constant because any difference might only be caused by crossover.
2.3. Estimation
Estimation might be based on equating observed to expected in Equations (1)–(6), but we recommend
to use maximum likelihood estimation, which will be covered in Section 4. For insight into the target of
estimation, consider when 𝛾∗1 = 𝛾1 and rearrange Equation (6) using Equations (4) and (5) so that
𝛾1 =
E(Y11)∕n11 − 𝜋11E(Y101)∕n101
(1 − 𝜋11)E(Y100)∕n100
. (7)
The numerator is a total proportion of events in treatment after crossover minus the proportion of events
in insistors after crossover, scaled by the proportion at risk at crossover in treatment. The denominator
is the proportion of events in the ambivalents in control after crossover, scaled by the proportion of
ambivalents at risk in treatment at crossover. This structure is very similar to for all-or-none compliance
[6]. Essentially, estimation of efficacy after crossover subtracts out the insistors from both arms by using
the observed insistors from the control arm.
3. Proportional-hazards model
The binomial model extends straightforwardly to an exponential model, but a proportional-hazards model
is more flexible, and so we focus on it next. Let the results from the trial for independent individuals
i = 1,… , n be (ti, 𝛿i) where ti is the continuous observation time and 𝛿i is equal to 1 if the event occurred
and 0 if right censored at the last follow-up. Denote treatment randomisation indicator ri to be 1 if sub-
ject i was randomised to treatment and 0 if control, and ci = 1 if an insistor and 0 if ambivalent. The
potential crossover time is si (cf. Figure 1). Then the hazard at time t ⩾ 0, conditional on covariates
xi = (xi1,… , xim) at baseline, is taken to be of form
𝜆(t ∣ ri, si, ci, xi;𝜽) = 𝜆0i(t)𝜓(t, ri, si, ci, xi;𝜽), (8)
where 𝜆0i(t) is a baseline hazard function (with an i subscript because it might be stratified so that 𝜆0i = 𝜆0j
if i and j are in the same strata, or not with 𝜆0i = 𝜆0), and
𝜓(t, ri, si, ci, xi;𝜽) = exp[𝛾{ri + I(t ⩾ si)(1 − ri)ci} + 𝜔ci + xi𝜷′], (9)
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where I(.) is the indicator function, prime denoting the transpose, and parameters 𝜽 = (𝛾, 𝜔, 𝛽1,… , 𝛽m).
The treatment effect parameter is 𝛾 , the effect of being an insistor 𝜔, and covariate effects 𝜷 =
(𝛽1,… , 𝛽m). The formulation is an extension of [7], but where the insistors receive the effect of treat-
ment only after crossing over. It is quite different than treating compliance as a time-dependent covariate,
which does not respect randomisation and leads to bias, because it allows for the latent strata in both
arms. The model does not include time-varying covariates, but this is unlikely to be restrictive for ran-
domised trials, where even static covariates are not commonly used other than by stratifying the baseline
hazard function.
The estimators that we develop in the next section require assumptions A1–A3 from Section 2 and the
following.
(A4b) Censoring is independent given covariates and independent of latent strata given covariates.
(A5a) Latent strata are independent of covariates, or
(A5b) latent strata are independent of covariates within defined groups.
(A6) Latent strata are independent of time at entry within defined groups.
A5a is needed for the partial likelihood estimator in the Section 4; the more relaxed A5b is for the full
likelihood estimator. Both are not an issue if no covariates are used in the model, and A5a was also used
by [7] in their partial-likelihood estimator. A6 is needed for both estimators. The assumptions A5 and A6
may be checked using the data after the offer to switch. If A5b and A6 are not met without groups, then
groups might be sought where they are met. As for the binomial estimator, one may test if the treatment
effect is constant before and after the offer.
An outline of a full maximum likelihood estimation algorithm is as follows; see Section 4 for technical
details. Firstly, the probability each individual is an insistor at baseline is computed given ?̂?; then the
baseline hazardmay be fitted conditional upon this and ?̂?; finally, 𝜽 are fitted given the baseline hazard and
insistor probability estimates. The approach used in this algorithm to estimate the proportion of insistors
at baseline (full likelihood) and through time (partial likelihood) is the biggest difference compared with
[7]. This is because in the all-or-none compliance case the proportion of switchers at risk through time
in the unobserved arm may be estimated simply as the observed number of switchers at risk. However,
the new algorithm could also be applied in the all-or-none case where the main practical difference is
that the estimate of the number of non-compliers at risk in the unobserved arm would change each time
there is an event in that arm, rather than only each time there is an event in the observed arm. The overall
profile-likelihood algorithm continues until convergence in the likelihood [9]. The partial likelihood is
asymptotically concave because it is the same form as for all-or-none compliance [7], so it offers a good
starting point for full maximum likelihood.
Inference may be based on profile likelihood. One approach that is not recommended is to use Wald
confidence intervals from the partial likelihood; these would underestimate variability by treating the
proportion of insistors at risk through time as known.
4. Maximum likelihood estimation
4.1. Binary model
In the first period in control (t = 0; r = 0) and the treatment arm in both periods (t = 0, 1; r = 1), the
probability of an event is
ptr = 𝜋trptr1 + (1 − 𝜋tr)ptr0, (10)
where ptrk was defined in Section 2 and 𝜋0r = 𝜋 is assumed constant for t = 0. There are five unknown
parameters in the primary model: the baseline probabilities 𝛼0, 𝛼1 (potentially different in both periods),
the insistor effect 𝜔 = 𝜔0 = 𝜔1 (common in both periods), the treatment effect 𝛾 = 𝛾0 = 𝛾1 = 𝛾∗1
(common in both periods) and the proportion of insistors at baseline 𝜋. The probability of being an insistor
at risk in treatment after the offer (𝜋11) is estimated as a function of the data and parameter estimates
(𝛼0, 𝜔, 𝛾, 𝜋), as discussed in Section 2. For the treatment arm (t = 0, 1; r = 1) and the control arm before
the offer (t = 0; r = 0), the likelihood is
Ltr ∝ p
ytr
tr (1 − ptr)ntr−ytr (11)
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and after the offer in control
L10 ∝
1∏
k=0
py10k10k (1 − p10k)
n10k−y10k . (12)
The complete likelihood
L ∝
1∏
t=0
1∏
r=0
Lrt (13)
may be used to form maximum likelihood estimates and profile-likelihood confidence intervals in the
usual manner.
4.2. Proportional-hazards model
4.2.1. Likelihood function. Before crossover and in the treatment group, we do not observe the latent
strata. Thus, if ti < si and ri = 0, or when ri = 1, then the likelihood for individual i is
Li(𝜽 ∣ ri, si, xi) = 𝜋iLi(𝜽 ∣ ri, ci = 1, xi) + (1 − 𝜋i)Li(𝜽 ∣ ri, ci = 0, xi) (14)
where 𝜋i = P(Ci = 1 ∣ ri, xi) is the probability a person is an insistor conditional on baseline covariates
xi and
Li(𝜽 ∣ ri, ci, xi) = 𝜆(ti ∣ ri, ci, xi;𝜽)𝛿iexp
{
−∫
ti
0
𝜆(u ∣ ri, ci, xi;𝜽)du
}
.
If the crossover is observed (ti ⩾ si and ri = 0), then Li is the product of two terms given later
in Equation (20). The first contribution is a survivor function P(ti > si ∣ ri = 0, si, xi), which is
of the same form as Equation (14); the second contribution when ci is known (ti ⩾ si) is 𝜆(ti ∣
ri, si, ci, xi;𝜽)𝛿iexp
{
− ∫ tisi 𝜆(u ∣ ri, ci, xi;𝜽)du
}
. The full likelihood for everyone is
L(𝜽) =
n∏
i=1
Li(𝜽 ∣ ri, si, xi),
and we will write l(𝜽), or just l, for the log likelihood.
4.2.2. Partial likelihood function. Consider when 𝜆0i(t) = 𝜆0(t) so that there are no baseline-hazard
groups. Then the partial likelihood is denoted
PL(𝜽) =
n∏
i=1
{
𝜂(ti, ri, si, xi)∑n
j=1 I(tj ⩾ ti)𝜂(ti, rj, si, xj)
}𝛿i
. (15)
When the latent stratum is unknown (rj = 0 and sj > ti, or rj = 1)
𝜂(ti, rj, sj, xj) = 𝜋(ti ∣ rj)𝜓(ti, rj, sj, cj = 1, xj) + {1 − 𝜋(ti ∣ rj)}𝜓(ti, rj, sj, cj = 0, xj),
where 𝜋(ti ∣ rj) is the conditional probability of being an insistor (cj = 1) still at risk in arm rj at time
ti. Note that we follow assumption A5a and assume 𝜋(ti ∣ rj, xj) = 𝜋(ti ∣ rj). When crossover status
is known (rj = 0 and sj ⩽ ti), then 𝜂(ti, rj, sj, xj) = 𝜓(ti, rj, cj, xj). For a model with different baseline
hazard functions for defined groups, the product of different partial likelihoods of form (15) for each
baseline-hazard group is taken.
4.2.3. Proportion of insistors. In this section, we develop a consistent estimator of the proportion of
insistors at risk through time given the event times, insistor effect𝜔 and the number of insistors at baseline
u, without a full probability survival model.
We take a group where C is independent of X (assumption A5b) and time at entry in the group (A6);
the following may be applied separately to all such groups. Then consider arm 0 where latent strata are
observed for tj ⩾ sj. The proportion of insistors at risk is to be updated at t′j = min(tj, sj) for j = 1,… , n0
individuals in arm 0, which is the crossover time sj if it is before the survival time tj, or tj otherwise. The
combination of censoring indicator 𝛿j and whether the individual was at risk at sj is classified using
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ej =
⎧⎪⎨⎪⎩
0 sj > tj and 𝛿j = 1 (event before offer to switch)
1 + cj sj ⩽ tj (at risk after offer)
3 sj > tj and 𝛿j = 0 (censored before the offer).
We take the order of individuals to be sorted ascending by t′j , so that for indices j ∈ (1,… , n0 − 1),
t′j ⩽ t
′
j+1. For a given u0 = u number of insistors in arm 0 at baseline and insistor effect 𝜔
′ = exp(𝜔), the
number uj and proportion of insistors at risk for j = 1,… , n0 are estimated iteratively using
𝜉j =
⎧⎪⎨⎪⎩
?̂?(t′j−1)𝜔
′∕{(1 − ?̂?(t′j−1)) + ?̂?(t
′
j−1)𝜔
′} ej = 0 (unknown stratum, event before the offer)
0 ej = 1 (ambivalent)
1 ej = 2 (insistor)
𝜋(t′j−1) ej = 3 (unknown stratum, censored before the offer)
(16)
so that ?̂?(t′j ) = ûj∕(n0 − j) where ûj = ûj−1 − 𝜉j. The rationale is as follows. When ej = 1, 2, then we
know whether the individual crossed over, and the number still at risk ûj at time t
′
j is updated accordingly.
When ej = 3, then ?̂?(t′j ) does not change because censoring is assumed independent of insistor status. If
ej = 0, then cj is unobserved and 𝜉j estimates the probability P(cj = 1 ∣ ej); compare with Equation (3)
for the binomial model. It arises from model (8) where
E{dN(t′j ∣ cj = 1)} =
𝜋(t′j )𝜔
′
1 − 𝜋(t′j )
E{dN(t′j ∣ cj = 0)}, (17)
using N(t ∣ cj) to denote a counting process that jumps by one when there is an event. For example,
if the arms are balanced with 𝜋(t′j ) = 0.5, but the insistor effect 𝜔
′ = 2, then for each event among
the ambivalents, (cj = 0) 𝜔′ = 2 events are expected in the insistors (cj = 1), that is, E{dN(t′j ∣ cj =
1)} = 2 × E{dN(t′j ∣ cj = 0)}. Similarly, if 𝜔
′ = 1 and there are twice as many insistors as ambivalents
(𝜋(t′j ) = 2∕3), then for each event among ambivalents, there will be 𝜋(t
′
j ){1 − 𝜋(t
′
j )}
−1 = 2 events
expected in the insistors. Although the survival model is in continuous time, a few ties are sometimes
tolerated. If t′j = t
′
j+1 = … = t
′
j+k are tied, then the suitable adjustment is to set the associated ûl = ûj+k
for l = j,… , j + k − 1.
Secondly, the number of insistors at baseline u may be estimated by maximum likelihood, given 𝜔.
The data are occasions when an individual crossed over or not, that is, when ej = 1, 2. For j = 1,… , n0,
if ej = 0 or 3, then the log-likelihood lj(u ∣ 𝜔) = 0, else
lj(u ∣ 𝜔) = (ej − 1)log{𝜋∗(t′j )} + (2 − ej)log{1 − 𝜋
∗(t′j )}, (18)
where the 𝜋∗(t′j ) = 𝜋(t
′
j ) if t
′
j > t
′
j−1, otherwise 𝜋
∗(t′j ) = 𝜋(t
′
j−k) where k selects the first crossover event
time equal to t′j . The 𝜋
∗(t′j ) definition is needed for ties when more than one event occurs at each point t
′
j ;
the same estimate of the proportion of insistors should be used for all of them. The proportion of insistors
at the start may be estimated by maximising the overall log-likelihood l(u ∣ 𝜔) =
∑n0
j=1 lj(u ∣ 𝜔).
Finally, given u and 𝜔, one may estimate the proportion of insistors at risk in the observed arm 0. If
the proportion of insistors at the start of the trial in arm 0 is estimated to be the same as in arm 1, then
one may use Equation (16) but for the unobserved arm 1.
4.2.4. Baseline hazard function. A baseline hazard function may be estimated for each baseline-hazard
group, so for simplicity take that 𝜆i0(t) = 𝜆0(t) for i = 1,… , n, where 𝜆0(t) is a step function with
unknown jumps Δi at each observed event time ti and that the times are sorted ascending. To estimate it,
we use the partial derivative
𝜕l
𝜕Δi
=
n∑
j=1
𝜕lj
𝜕Δi
.
In the following, we drop conditioning arguments from the setup except c in reduce notational burden,
but they are still present. Firstly, consider j = 1,… , n where rj = 1, that is, those in the treatment arm
whose crossover status cj is not observed. Let 𝜋j = P(Cj = 1 ∣ xj), then in this case
Lj = 𝜋j𝜆
𝛿j
j (cj = 1)exp{−Λ(cj = 1)} + (1 − 𝜋j)𝜆
𝛿j
j (cj = 0)exp{−Λ(cj = 0)}
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so that
lj = log(Δ
𝛿j
j ) + log(Aj)
where
Aj = 𝜋j𝜓(cj = 1)𝛿jexp{−Λ(cj = 1)} + (1 − 𝜋j)𝜓(cj = 0)𝛿jexp{−Λ(cj = 0)}.
For j = i,… , n, because
𝜕exp{−Λ(tj)}∕𝜕Δi = −𝜓exp{−Λ(tj)},
we have that, for j = i,… , n such that rj = 1,
𝜕lj
𝜕Δi
= 𝛿i∕Δi −
n∑
j=i
[𝜋j𝜓(cj = 1)(1+𝛿j)exp{−Λ(tj ∣ cj = 1)}
+ (1 − 𝜋j)𝜓(cj = 0)(1+𝛿j)exp{−Λ(tj ∣ cj = 0)}]∕Aj
∶= 𝛿i∕Δi −
n∑
j=i
a1j
∶= 𝛿i∕Δi + a1,
(19)
where ∶= denotes definition. Now consider j = 1,… , n in arm 0. When insistor status is not observed
because tj < sj, then the same form as Equation (19) applies; denote it a2. If tj ⩾ sj, then
Lj = [𝜋jexp{−Λ(sj ∣ cj = 1)} + (1 − 𝜋j)exp{−Λ(sj ∣ cj = 0)}]
× 𝜆(tj ∣ cj)𝛿jexp{−Λ(sj, tj ∣ cj)}
(20)
where Λ(sj, tj ∣ cj) = ∫ tjsj 𝜆j(v ∣ cj)dv, so that
lj = log{A∗j } + log(Δ
𝛿j
j ) − Λ(sj, tj ∣ cj) + log(𝜓
𝛿j)
where
A∗j = 𝜋jexp{−Λ(sj ∣ cj = 1)} + (1 − 𝜋j)exp{−Λ(sj ∣ cj = 0)}.
Then for j = i,… , n such that sj ⩽ ti
𝜕lj
𝜕Δi
= −𝜓(cj) + I(j = i)𝛿j∕Δi
∶= a(1)3j
and for when sj > ti
𝜕lj
𝜕Δi
= −[𝜋j𝜓(cj = 1)exp{−Λ(sj ∣ cj = 1)}+
(1 − 𝜋j)𝜓(cj = 0)exp{−Λ(sj ∣ cj = 0)}]∕A∗j + I(j = i)𝛿j∕Δi
∶= a(2)3j ,
so that overall for those observed to crossover (tj > sj)
𝜕l
𝜕Δi
=
n∑
j=i
a(1)3j I(sj < ti) + a
(2)
3j I(sj ⩾ ti)
∶= a3.
Overall, we have
𝜕l
𝜕Δi
= I(ri = 1)a1 + I(ri = 0){I(ti < si)a2 + I(ti ⩾ si)a3}. (21)
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Setting Equation (21) to zero provides a route to estimation of Δi for i = 1,… , n, conditional on 𝜽 and
𝜋. If 𝛿i = 1 and 𝛿i+1 = 1 and it is not true that ti < sj < ti+1 for j = i + 1,… , n, then
Δ−1i − Δ
−1
i+1 = I(ri = 1)a1i + I(ri = 0){I(ti < si)a2i + I(ti ⩾ si)a3i}
∶= D∗i
(22)
say. This simple form arises because the i+ 1,… , n terms in the a1, a2, a3 summations over j cancel out.
Extra terms are needed with censoring, and if ti < sj < ti+1 for j = i + 1,… , n because the derivatives
of those j’s likelihood contribution with respect to Δi do not cancel out. Thus, more generally for two
events at times i and i + k with censored observations between from i + 1,… , i + k − 1
Δ−1i − Δ
−1
i+k =
i+k−1∑
j=i
D∗j +
n∑
j=i+k
I(rj = 0)I(ti < sj ⩽ ti+k)(a
(2)
3j − a
(1)
3j )
∶= Di
(23)
say, where the first summation is for the censored observations and the second summation is for those
observed to crossover in arm 0 between ti and ti+k. Now Δ−1i+1 = Δ
−1
i −Di, and the problem of estimating
the baseline given 𝜽 is reduced to determining Δi for the first i (i.e. smallest ti) with 𝛿i = 1. This may be
achieved using a root-finding algorithm for the score function.
The above extends when there are ties. Suppose that wi times are tied following ti (ti = ti+1,… , ti+w−1),
and wi+k following ti+k. Then the left-hand side of Equation (23) is wiΔ−1i − wi+kΔ
−1
i+k.
5. Example
We next apply the binomial estimator to the data from two monotherapy arms in the BIG1-98 trial, where
postmenopausal women who had been diagnosed with hormone-receptor positive invasive breast cancer
were randomised to receive 5 years of tamoxifen (control) or letrozole (treatment). Following the primary
analysis [1], women who were still receiving tamoxifen were unblinded [2]. In this example, one might
question the model assumption that the treatment effect of letrozole is that same after taking tamoxifen,
as at baseline (i.e. 𝛾1 = 𝛾∗1 in the notation of Section 2). This issue was actually investigated by planned
crossover arms in the BIG-1 98 trial, where little difference was found [10], so we proceed under the
assumption.
Table I shows a summary of data previously reported [10, 11]. The results before unblinding are in
period 0; period 1 is the time after that until 12-year follow-up. Of 2459 women randomised to tamoxifen,
some 25% received letrozole after unblinding, with most crossing over between 3 and 5 years since
randomisation.
Table II shows published results from fitting ITT and inverse probability of censoring weighting
(IPCW) stratified proportional hazards models using individual time-to-event data [10]. The per-protocol
Table I. Disease-free survival results from BIG-1 98 trial
[10, 11].
Period At risk Number (%) events
Letrozole 0 2463 352 (14.3)
Tamoxifen 0 2459 418 (17.0)
Letrozole 1 2045 294 (13.0)
Tamoxifen 1 1975 309 (13.8)
– do not cross over 1 1356 251 (15.5)
– cross over 1 619 58 ( 9.4)
The data in period 0 were reported by [11]. The number of events
in period 1 are the 12 year follow-up analysis [10] minus events in
period 0. The number at risk in the second period was calculated
as the number randomised minus the number (i) of disease-free
survival events in the first period, (ii) lost to follow up and (iii)
withdrawn (Table A2 in [11]), split by the reported 619 who chose
to cross over [10].
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Table II. Disease-free survival treatment effect esti-
mates (95% CI) from BIG-1 98 trial 12-year update
[10].
Estimate (95%CI)
Hazard ratio ITT 0.86 (0.78, 0.96)
IPCW 0.82 (0.74, 0.92)
Relative risk ITT 0.89 (0.81, 0.97)
Efficacy (?̂?) 0.86 (0.77, 0.96)
– t = 0 (?̂?0) 0.84 (0.74, 0.96)
– t = 1 (?̂?1) 0.90 (0.74, 1.07)
– [Het. test] [𝜒21 = 0.32]
Het. test, heterogeneity likelihood-ratio test.
Figure 4. Profile likelihood surface to obtain confidence intervals for separate treatment effects in (a) the first
period and (b) the second period, for disease-free survival in the example. The dotted lines and points are the 95%
confidence interval. [Colour figure can be viewed at wileyonlinelibrary.com]
approach that censors women who ceased to comply with their randomised allocation is not suitable for
these data because there was strong evidence that those who crossed over had a different baseline risk
than those who did not; the group who crossed over from tamoxifen in Table I had a lower proportion
of events (9.4%) than the letrozole arm (13.0%). Thus, the randomised balance of risk factors between
comparison groups is almost certainly lost in a per-protocol analysis.
An ITT analysis was applied using just the number of events and women in both arms. In general,
relative risks are closer to unity than hazard ratios, so it is not surprising that the relative risks for ITTwere
closer to unity than the hazard ratio in Table II. However, differences were small and ITT inference was
unchanged. The binomial efficacy estimate for disease-free survival was of a similar order less than the
ITT estimate, in comparison with the IPCW estimate. This provides some support to the IPCW estimate
for disease-free survival.
We also used the model to allow for different treatment effects in each period. There was little hetero-
geneity between the point estimates of efficacy before and after unblinding (Table II; Figure 4). However,
the wide confidence intervals after crossover indicate that further follow-up would be useful to deter-
mine whether disease-free survival was better in the first period. There was also almost no evidence for
a difference in 𝜔0 and 𝜔1 (data not shown).
A limitation of the example is that it is best viewed as a demonstration of the method. Firstly, the actual
number at risk in the second period was only estimated on the basis of published data (although small
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changes to these numbers will not materially affect results). Secondly, application of the proportional-
hazards model on individual data would also be a better comparison with IPCW. Finally, we were unable
to apply either estimator for mortality endpoints because the subdivision of data illustrated by Figure 3
would be needed.
6. Simulations
The following simulations consider the performance of the full and partial likelihood estimators for dif-
ferent treatment and insistor effects, as the level of information on the treatment effect changes from
censoring. Nelder–Mead simplex algorithms were used for both full and partial likelihood estimation,
but very little difference was seen to a Broyden–Fletcher–Goldfarb–Shanno algorithm (not reported);
Brent–Dekker algorithms estimated the insistor proportions and baseline hazard function [12].
Survival times were simulated from an exponential distribution. The simulation was set up so that there
were three periods in follow-up time: before, during and after crossover. The period during crossover was
the same length as the period before it. We considered two censoring scenarios (i) with censoring where
an expected 5% events occurred before the first crossover in the lowest hazard group, and 5% events
after the last crossover, and (ii) no censoring with an expected 10% of events before the first crossover in
the lowest hazard group. For example, if the hazard was less for insistors and the treatment group, then
the lowest hazard group was insistors randomised to treatment. One thousand individuals were in each
arm, and the chance of being an insistor was 25% in both arms, but the number at baseline was sampled
independently in both arms from a binomial distribution. The treatment effect (𝛾) was 7/10 or 10/7; the
effect of being an insistor (𝜔) was either 0.2 or 2.0.
The pseudo algorithm used to generate the data is as follows. For r = 0, 1 and i = 1,… , nr individuals
in arm r with maximum follow-up F and an event-rate pre-crossover 𝜆ar(ci) and post-crossover 𝜆pr(ci)
conditional on underlying crossover trait ci: sample (i) crossover trait ci at baseline fromP(ci = 1) = 0.25;
(ii) crossover time si from a uniform distribution between 0 and 1 {U(0, 1)} plus 1; (iii) survival time ti1
from an exponential distribution with pre-crossover rate 𝜆ar(ci); (iv) survival time ti2 from an exponential
distribution with post-crossover rate 𝜆pr(ci). Then calculate (i) unobserved survival time (no censoring)
tui = ti1 if ti1 ⩽ si; else t
u
i = si + ti2; (ii) observed survival time (with censoring) ti = min(t
u
i , F); and (iii)
event status di = 1 if ti < F; else di = 0.
Full and partial likelihood estimators are compared in Table III. Mean bias was very small; for example,
0.467 for ?̂? from the partial likelihood in scenario 4 implies that the mean estimated treatment effect was
0.699 = exp{(1 + 0.00467) × log(0.7)}. The full likelihood bias was less than the partial likelihood for
both the treatment effect 𝛾 and insistor effect 𝜔, but their variances were very similar. There was also
very little difference in the estimated proportion of insistors at baseline. Thus, overall, the full and partial
Table III. Simulation results of FL and PL estimators.
Scenario 1 2 3 4 5 6 7 8
Treatment exp(𝛾) 7/10 7/10 7/10 7/10 10/7 10/7 10/7 10/7
Switching exp(𝜔) 0.2 0.2 2.0 2.0 0.2 0.2 2.0 2.0
Censoring Y N Y N Y N Y N
(a) Mean bias (%) of log estimates
𝛾 FL −0.002 0.004 −0.004 0.003 0.006 −0.003 0.007 0.001
𝛾 PL −0.231 0.340 0.533 0.467 0.666 −0.654 −0.037 −0.275
𝜔 FL 0.009 −0.003 −0.019 0.002 0.015 0.002 −0.003 0.001
𝜔 PL 0.835 −0.527 −1.078 0.130 1.522 −0.069 −0.259 −0.033
(b) Variance of log estimates
𝛾 FL 0.485 0.377 1.388 0.289 0.515 0.449 1.281 0.274
𝛾 PL 0.485 0.407 1.405 0.289 0.519 0.484 1.284 0.282
𝜔 FL 6.597 2.295 5.944 0.994 5.067 1.194 3.831 1.409
𝜔 PL 6.612 2.066 6.005 0.993 5.078 1.210 3.849 1.399
(c) Percent (%) of insistors at baseline estimates ?̂?
Mean FL 25.056 25.116 24.971 25.042 24.998 25.073 25.016 25.034
Mean PL 25.059 25.118 24.989 25.041 24.997 25.091 25.020 25.022
SD FL 1.579 1.910 1.732 1.848 1.447 1.589 1.786 2.013
SD PL 1.580 1.741 1.736 1.848 1.447 1.603 1.787 2.025
FL, full likelihood; PL, partial likelihood.
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Table IV. Bootstrap estimates of parameter uncertainty using partial likelihood
estimator.
Scenario 1 2 3 4 5 6 7 8
Var(?̂?) 0.485 0.407 1.405 0.289 0.519 0.484 1.284 0.282
Mean bootstrap 0.503 0.412 1.450 0.295 0.548 0.476 1.181 0.275
SD bootstrap 0.053 0.049 0.235 0.033 0.063 0.067 0.161 0.029
Var(?̂?) 6.612 2.066 6.005 0.993 5.078 1.210 3.849 1.399
Mean bootstrap 7.296 2.003 6.581 1.005 5.439 1.209 3.683 1.319
SD bootstrap 2.111 0.473 1.376 0.173 1.120 0.229 0.568 0.258
likelihood estimators had similar performance in a setting where the model assumptions were met, and
assumption A5a was appropriate.
To evaluate the use of a simple bootstrap for inference, Table IV presents some results of resampling
with replacement individuals in each arm in each simulation sample. Two hundred bootstrap resamples
were made in each sample, and an estimate of the variance of the parameter estimate was obtained. The
table shows that this matched the observed variance from the 1000 simulation replicates at each scenario
quite closely. Because the variance of the full likelihood matched that of the partial likelihood quite
closely in Table III, one might just bootstrap the partial likelihood as computational time becomes more
of a consideration.
7. Conclusion
Themethods in this paper are applicable for analysis of trials with selective crossover arising due to results
from early efficacy endpoints and preserve randomisation. Our binary estimator is relatively simple to
implement, but the proportional-hazards model is more involved. An R package [13] with code for both
is available on request. We end by discussing the model assumptions in relation to other methods, and
comment on other breast cancer trials where treatment efficacy might be estimated.
The most common methods to account for selective crossover in practice are IPCW [14] and
g-estimation [15,16]. IPCW censors individuals when they cease to comply with randomised allocation,
but up-weights those who do comply and have similar characteristics to the non-compliers, as judged by
a chosen statistical model. The problem is that the assumptions required to guarantee that randomisation
is maintained cannot be verified because it is not possible to check the randomised balance of factors that
have not been measured. G-estimation involves predicting the outcome for each person who switches
treatment to be that expected if they had not switched. It is often accomplished through an accelerated
failure-time model [17]. In contrast with IPCW, randomisation is maintained. A disadvantage is that it
impossible to assess the assumed effect of treatment on the insistors after the offer to switch because
there is no comparison group: all insistors receive treatment after the offer. It is also not possible to allow
for time-dependent treatment effects. Other advantages and disadvantages of these methods have been
discussed more fully elsewhere [18, 19].
Although inverse probability weighting and g-estimation make important untestable assumptions that
are not required by our method, they may have better statistical performance than our estimators when
their assumptions are most closely met. For instance, assumptions A5b and A6 might be restrictive for
a particular data set. We also note that assumption A1 precludes a stochastic time of crossover, perhaps
arising due to the health of a participant though time when randomised to control, but inverse probability
weighting and g-estimation do not require this assumption. An important example of this in oncology is
crossover after progression-free survival in advanced disease.
Other oncology trials appear to be suitable for our estimators. The open-label ABCSG-8 addressed a
similar issue to BIG-1 98 and after publication of initial results approximately 9% crossed over from the
tamoxifen arm [20]. The MA.17 trial showed superiority of letrozole over placebo for postmenopausal
women with hormone receptor-positive breast cancer following about 5 years of tamoxifen [21] and
almost two-thirds of the patients in the control arm crossed over after unblinding. In the open-label
Herceptin Adjuvant (HERA) trial, more than half of patients in the ‘control’ group chose to cross over
after a first interim analysis [22]. With such substantial crossover, methods such as those in this article
are clearly needed to help assess longer-term differences between treatments.
In conclusion, we recommend that treatment efficacy and our estimators thereof be considered for trials
with selective crossover in one arm arising due to results from early efficacy endpoints.
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